PAR 9.43% 24.0¢ paradigm biopharmaceuticals limited..

Ann: R&D Investor Presentation, page-28

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 1,770 Posts.
    lightbulb Created with Sketch. 1950
    Nope.

    A "Phase 3-desirable asset for partnering" is simply consistent with Paul's assertion at the AGM that he expects interest to ramp significantly post-IND. That's all.

    In today's Q&A Paul has reiterated that they have a valuation in mind, will leave the door open for a capital raise if required to get us there, and that a deal is actually most likely after Para003 readout in Q3 2023.
 
watchlist Created with Sketch. Add PAR (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.